Grottick A J, Wyler R, Higgins G A
PRBN-B, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.
Pharmacol Biochem Behav. 2001 Dec;70(4):505-13. doi: 10.1016/s0091-3057(01)00639-6.
SIB-1553A is a novel ligand with reputed agonist selectivity at nicotinic receptors containing the beta(4) subunit. As such, it represents an interesting pharmacological tool with which to probe the function of nicotine receptor subtypes. In the present studies, we compared SIB-1553A with nicotine in its ability to stimulate locomotion and to enhance attention in rats as assessed using the five-choice serial reaction time task (5-CSRTT). In nicotine-naive rats, SIB-1553A (10-40 mg/kg) induced a comparable increase in locomotion to nicotine (0.4 mg/kg), whereas in nicotine-sensitised rats, an enhanced locomotor response was seen to nicotine (0.4 mg/kg) but not to SIB-1553A (10-80 mg/kg). Similarly, chronic treatment with either SIB-1553A or nicotine did not lead to a cross-sensitised locomotor response. Unlike nicotine, SIB-1553A-induced locomotion was insensitive to antagonism by either mecamylamine (1 mg/kg) or DH beta E (3 mg/kg), suggesting a non-nicotinic mechanism. In young and aged rats, nicotine (0.4 mg/kg) enhanced attention as demonstrated by an increase in response accuracy and speed. SIB-1553A (3-10 mg/kg) did not mimic any of these changes and at the highest dose tended to disrupt performance. These results lend further support to the involvement of a high affinity site, possibly alpha(4)beta(2), in the locomotor and attentional-enhancing properties of nicotine.
SIB - 1553A是一种新型配体,对含有β(4)亚基的烟碱样受体具有公认的激动剂选择性。因此,它是一种有趣的药理学工具,可用于探究烟碱样受体亚型的功能。在本研究中,我们将SIB - 1553A与尼古丁在刺激大鼠运动和增强注意力方面的能力进行了比较,使用五选择连续反应时任务(5 - CSRTT)进行评估。在未接触过尼古丁的大鼠中,SIB - 1553A(10 - 40毫克/千克)引起的运动增加与尼古丁(0.4毫克/千克)相当,而在对尼古丁敏感的大鼠中,观察到尼古丁(0.4毫克/千克)能增强运动反应,但SIB - 1553A(10 - 80毫克/千克)则不能。同样,用SIB - 1553A或尼古丁进行慢性治疗均未导致交叉敏感的运动反应。与尼古丁不同,SIB - 1553A诱导的运动对美加明(1毫克/千克)或二氢β-刺桐定(3毫克/千克)的拮抗作用不敏感,提示其作用机制非烟碱样。在年轻和老年大鼠中,尼古丁(0.4毫克/千克)可提高反应准确性和速度,从而增强注意力。SIB - 1553A(3 - 10毫克/千克)并未模拟这些变化,且在最高剂量时往往会干扰行为表现。这些结果进一步支持了高亲和力位点(可能是α(4)β(2))参与尼古丁运动和注意力增强特性的观点。